SLNO
Soleno Therapeutics Inc.
$45.11
+$0.16(+0.36%)
40
Overall
55
Value
25
Tech
--
Quality
Market Cap
$2.54B
Volume
1.31M
52W Range
$41.50 - $90.32
Target Price
$117.36
Company Overview
| Mkt Cap | $2.54B | Price | $45.11 |
| Volume | 1.31M | Change | +0.36% |
| P/E Ratio | -14.5 | Open | $44.55 |
| Revenue | -- | Prev Close | $44.95 |
| Net Income | $-175.8M | 52W Range | $41.50 - $90.32 |
| Div Yield | N/A | Target | $117.36 |
| Overall | 40 | Value | 55 |
| Quality | -- | Technical | 25 |
No chart data available
About Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Diagnostics & Research
Latest News
Soleno Therapeutics Announces $100M Share Buyback Plan
TipRanks Auto-Generated Newsdesk•12 days ago
Cantor Fitzgerald Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)
TipRanks Auto-Generated Intelligence Newsdesk•18 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLNO | $45.11 | +0.4% | 1.31M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Soleno Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW